| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_36a3a3f127678c22297e5c39dc2b1b99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c0f063f42910f1ced662e533f4ae6bec |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A90-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-54391
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06F7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H10-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-54386
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-54388
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G05B15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-7275 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G06F7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G05B15-00 |
| filingDate |
2016-04-05^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-03-27^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45c5da65650818e5d7882fc346a47068 |
| publicationDate |
2018-03-27^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9927443-B2 |
| titleOfInvention |
Risk assessment for therapeutic drugs |
| abstract |
Methods to estimate safety and/or efficacy of therapeutic drugs, which include portable devices for anti-drug antibody (ADA) testing and databases containing anonymized data from humans and/or animal models, and related analyses, are provided. These methods and compositions can be used in various applications, including but not restricted to the following: uniform testing of patients for ADA; selection of therapeutic drug for patient treatment; evaluation of the need to change therapeutic drug or to apply tolerance regimens; selection of patients for clinical trials; comparison of therapeutic drugs marketed for a given disease and also gene therapy; scientific guidance for discovering and/or developing therapeutic drugs; postmarketing surveillance of therapeutic drugs. |
| priorityDate |
2015-04-10^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |